Halozyme Earnings Call Highlights Royalty-Fueled Growth

Halozyme Therapeutics ((HALO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Halozyme Therapeutics’ latest earnings call struck an upbeat tone, with management leaning into strong double‑digit growth and a visibly expanding royalty engine. Executives acknowledged higher leverage, rising operating expenses and execution risks, but framed them as investments to extend the ENHANZE franchise, launch Hypercon and support multiple new deals, leaving an overall impression of confident, measured ambition.

Top-Line Acceleration Underpins Growth Story

Halozyme posted Q1 2026 revenue of about $377 million, up roughly 42% year over year, signaling robust demand across its portfolio. Management emphasized that both direct product sales and supplies to partners contributed, suggesting the business is benefiting from broad-based adoption rather than a single product spike.

Royalty Engine Delivers Outsized Gains

Royalty revenue reached about $241 million in the quarter, climbing roughly 43% from a year earlier. The company tied this to the continued shift of major biologics to ENHANZE-enabled subcutaneous formulations, reinforcing the thesis that Halozyme’s model scales as more partners convert or launch SC versions.

Profitability Strength and EPS Expansion

Adjusted EBITDA came in at $229.5 million, up around 42% year over year, demonstrating that margins remain robust even as the company integrates acquisitions. Non-GAAP diluted EPS rose more than 40% to $1.60, with GAAP EPS at $1.22, giving equity investors tangible evidence that earnings power is tracking ahead of revenue growth.

Reaffirmed Multi-Year Guidance Builds Confidence

Management reaffirmed 2026 revenue guidance of $1.71–$1.81 billion, implying roughly 22%–30% growth versus 2025. Royalty revenue is expected to reach $1.13–$1.17 billion and adjusted EBITDA $1.125–$1.205 billion, with non-GAAP EPS projected at $7.75–$8.25, underscoring confidence in the durability of current momentum.

ENHANZE Royalties Offer Long-Duration Upside

The company estimates that the 10 currently approved ENHANZE products had generated only about 25% of their projected lifetime royalties by the end of 2025. Roughly two-thirds of the remaining expected royalty stream is forecast to accrue between 2026 and 2032, highlighting a sizable backlog that could sustain high-margin growth for years.

Flagship Products Drive Royalty Performance

DARZALEX remained the cornerstone, with about $4 billion in Q1 global sales and 18% operational growth fueling $129 million in Halozyme royalties, up 26% year on year. VYVGART Hytrulo and PHESGO also delivered, with VYVGART Hytrulo royalties more than doubling and PHESGO royalties rising 25%, underscoring the breadth of ENHANZE’s commercial footprint.

Pipeline and Deal Flow Extend the Franchise

Halozyme expects up to 13 additional ENHANZE products to be in development by the end of 2026, supporting potential launches from 2029 onward. During 2026 it signed three new collaboration and licensing agreements, including with GSK, Vertex and ORKA, while partners initiated new Phase I studies, reinforcing visibility into future royalty streams.

Hypercon Positioned as Next Major Growth Leg

Hypercon, Halozyme’s high-concentration platform, is emerging as a key longer-term driver, though on a delayed timetable. First Phase I trials are now projected for the first half of 2027 with potential launches in 2030–2031, and management believes Hypercon could ultimately generate about $1 billion in royalties by the mid-2030s.

Capital Returns and Allocation Discipline

Halozyme announced a new $1 billion share repurchase authorization and expects to buy back at least $400 million of stock in 2026, implying an attractive ongoing buyback yield. Management stressed that capital will also be directed toward organic R&D, including ENHANZE, Hypercon and Surf Bio, as well as retiring notes maturing in 2027 and 2028.

Operational Leverage and Cash Generation

Executives highlighted strong conversion of revenue into free cash flow, which supports both aggressive buybacks and steady deleveraging. This operational efficiency is central to the investment case, as it allows Halozyme to fund growth initiatives while returning significant capital to shareholders without stretching the balance sheet.

Leverage Elevated but on a Declining Path

Net leverage stood at about 2.5 times at quarter end, reflecting the Hypercon and Surf Bio acquisitions that expanded the technology platform. Management expects this ratio to fall to roughly 1.2 times by the end of 2026, assuming execution on earnings growth and capital return plans, which would materially de-risk the balance sheet.

Higher Operating Expenses Reflect Integration Phase

R&D spending jumped to $25.6 million from $14.8 million, while SG&A rose to $57.9 million from $42.4 million, driven largely by integration costs and investment into newly acquired platforms. The company framed these increases as temporary steps to build capability and argued that they are manageable within its high-margin model.

Hypercon Execution and Timing Risks

Hypercon’s value proposition depends on successful manufacturing scale-up and reliable clinical supply, both of which remain in build-out. With Phase I starts pushed into 2027 and launches targeted for early next decade, investors must factor in timing and execution risk before Hypercon can materially contribute to revenue.

IP Duration and Royalty Protection Challenges

Halozyme’s base composition-of-matter patents expire in 2029 in key markets, making future royalty duration increasingly reliant on co-formulation patents and related protections. Management underscored ongoing work to secure these protections, but their success and enforceability remain critical swing factors for the length of the royalty tail.

Deal Timing and Competitive Uncertainties

The company described a high bar for further drug-delivery M&A and does not expect to find another qualifying target in 2026, leaving inorganic growth timing uncertain. Management also pointed to limited visibility on competitor strategies and certain partner activities, reinforcing that competitive technologies and partner choices remain key external risks.

Guidance and Outlook Emphasize Sustained Expansion

Halozyme reaffirmed its 2026 and 2026–2028 outlook, calling for total 2026 revenue of $1.71–$1.81 billion and royalty revenue of $1.13–$1.17 billion, with ENHANZE royalties alone expected to surpass $1 billion. The company projects adjusted EBITDA margins above 65%, trending toward 70%, alongside falling leverage and meaningful share repurchases, signaling a strategy built on durable, cash-rich growth.

In sum, Halozyme’s earnings call painted a picture of a royalty-driven biotech with strong current fundamentals and a deepening long-term pipeline. While higher leverage, elevated spending, IP timelines and Hypercon execution add risk, management’s reaffirmed guidance, cash generation and aggressive capital return plan offer shareholders a compelling, albeit execution-dependent, growth narrative.